What Is Quantitative Proteomics? Methods, Techniques, And Applications

What Is Quantitative Proteomics?
Label-Based Quantification
Label-Free Quantification
DDA vs. DIA in Quantitative Proteomics
Proteomics Data Quality
Proteomics in Action: Applications and Innovations
References and Further Reading

Quantitative proteomics enables precise measurement of protein abundance across biological systems using label-based and label-free mass spectrometry approaches. It provides critical insights into cellular function, disease mechanisms, and clinical applications through robust analytical and computational workflows.

Image credit: Sodel Vladyslav/Shutterstock.com

Quantitative proteomics provides a framework for the precise measurement of protein abundance across biological samples, linking molecular changes to cellular processes and clinical outcomes. The strategies used are broadly divided into label-based and label-free approaches, each relying on defined analytical and computational principles.

This article examines how these approaches operate within experimental workflows, outlining the concepts that enable accurate and reproducible protein quantification and highlighting their role in ensuring rigor in proteomics studies.

What Is Quantitative Proteomics?

Quantitative proteomics enables systematic analysis of protein levels in different biological states, allowing comparisons between experimental conditions, time points, or sample groups. Unlike qualitative proteomics, which identifies proteins present in a sample without measuring abundance, quantitative approaches determine the magnitude of these differences.¹

Protein quantification is essential for understanding biological variation, as many cellular processes are regulated through changes in protein expression, post-translational modifications (PTMs), and protein complex formation. Measuring these changes helps map signaling dynamics and cellular responses to environmental stimuli, revealing how these processes may be altered in disease and identifying potential therapeutic targets.^2,3

Importantly, proteins represent intermediate phenotypes between genetic variation and observable traits, providing more direct insight into cellular function than genomics alone.¹

Two conceptual principles underpin quantitative proteomics: relative and absolute quantification. Relative quantification compares protein abundance between samples, such as treated versus untreated cells or healthy versus diseased tissues, to reveal proteins that differ across biological contexts.⁴

Absolute quantification measures the exact amount of protein in a sample, expressed as concentration or copy number. It often relies on calibrated standards or isotope-labeled reference peptides and is particularly valuable for quantitative systems biology models and pharmacological studies. Absolute approaches also enable estimation of protein stoichiometry within complexes and pathways, which is critical for understanding molecular interactions and network behavior.^2,4

Label-Based Quantification

Label-based quantification introduces stable isotopes into proteins or peptides to distinguish molecules from different samples within a single mass spectrometry (MS) run, enabling accurate comparison of protein abundance. These strategies include metabolic, chemical, and enzymatic labeling approaches.⁵

Metabolic labeling incorporates isotopes into proteins during cell growth. A widely used method is Stable Isotope Labeling by Amino acids in Cell culture (SILAC), in which cells are cultured in media containing isotope-labeled amino acids. After labeled and unlabeled samples are combined and analyzed by MS, peptides appear as pairs with distinct mass differences, reflecting relative protein abundance.^2,5

Chemical labeling involves the introduction of isotopic tags after protein extraction and digestion. A common approach is to use isobaric tagging reagents, such as tandem mass tags (TMT) or isobaric tags for relative and absolute quantification (iTRAQ), for relative and absolute quantification. Fragmentation during tandem MS releases reporter ions with distinct masses that identify the original sample and allow quantification of peptide abundance. This approach also enables multiplexing, allowing multiple samples to be analyzed simultaneously and improving throughput in comparative studies.^2,5

For example, iTRAQ-based workflows combined with targeted MS (e.g., PRM) enable both discovery and validation phases in biomarker studies, improving confidence in differentially expressed proteins³.

Enzymatic labeling introduces isotopes during protein digestion or peptide modification. For example, isotopic oxygen can be incorporated during enzymatic cleavage using water enriched with oxygen-18, providing another means of generating measurable mass differences.⁵

Each labeling approach offers distinct advantages and limitations. For instance, SILAC provides high quantitative accuracy because samples are combined early in the workflow, minimizing variation during sample preparation; however, it is largely restricted to cell culture systems. Alternatively, chemical labeling permits simultaneous analysis of multiple samples, although ratio distortion (also termed ratio compression) can arise from co-isolation and co-fragmentation of interfering peptides in MS2 spectra.²

In addition to these method-specific considerations, label-based approaches can involve higher costs, greater sample preparation complexity, and reduced experimental flexibility compared with alternative strategies.^2,5

Label-Free Quantification

Label-free quantification measures protein abundance without isotopic labels, relying instead on peptide signal intensity or detection frequency across multiple MS runs.⁶

One common approach is intensity-based quantification, which measures peptide chromatographic peak intensity using liquid chromatography–mass spectrometry (LC–MS). Because signal intensity reflects protein abundance, extracted ion chromatogram analysis can align and integrate signals across runs to estimate relative protein levels. However, quantitative accuracy depends on consistent sample preparation, chromatographic performance, and instrument stability across runs.²

Another label-free method is spectral counting, which estimates protein abundance from the number of tandem MS spectra assigned to a protein. Although higher-abundance proteins generally yield more spectra, this approach is less precise than intensity-based methods and less effective at detecting small fold changes or low-abundance proteins.⁶

Compared with label-based methods, label-free quantification delivers flexible, cost-efficient, and scalable measurements, though it is particularly sensitive to missing values arising from stochastic sampling and detection limits in LC–MS workflows.⁶

Need to save this for later? Download your free PDF copy here.

DDA vs. DIA in Quantitative Proteomics

The effectiveness of label-free quantification depends on the underlying MS acquisition strategy, which determines how peptides are selected and measured. In data-dependent acquisition (DDA), the instrument selects the most intense peptide ions for fragmentation during each scan cycle. While widely used, DDA can lead to missing data when low-abundance peptides are inconsistently selected.^6,7

Data-independent acquisition (DIA) addresses this limitation by systematically fragmenting all peptides within defined mass windows. Because all precursor ions are fragmented, DIA helps ensure more uniform peptide detection across samples.^1,7

As a result, DIA workflows often generate more comprehensive quantitative data sets, particularly for complex samples. DIA methods combine high reproducibility with broad proteome coverage, making them particularly suitable for clinical and large-cohort studies. However, they still require advanced computational analysis and spectral libraries to interpret the resulting fragmentation patterns.^1,7

Proteomics Data Quality

Accurate and reproducible quantitative proteomics depends on rigorous experimental design and robust data processing. Despite these measures, analytical challenges persist, including the broad dynamic range of proteomes and technical factors such as incomplete peptide detection, interference, and limited sensitivity, which can compromise quantitative reliability.^2,7

To help address these issues, normalization is a key step, which corrects systematic differences between samples or instrument runs by adjusting total signal intensity, peptide distributions, or internal reference proteins, thereby reducing technical variation.⁸

This is further reinforced by the use of internal standards; for example, stable isotope-labeled peptides can be spiked into samples at known concentrations to provide reference points for evaluating measurement accuracy.⁹

In addition, quality control (QC) metrics offer another layer of assurance, with parameters such as peptide identification confidence, instrument stability, and chromatographic reproducibility monitored throughout the workflow to detect potential issues.¹⁰

It is also important to account for both biological variation, arising from inherent differences between samples, and technical variation, resulting from sample preparation, instrument performance, or data processing. Implementing replication at both levels helps distinguish meaningful biological signals from experimental noise.¹¹

Alongside these analytical controls, statistical evaluation is essential for validating observed differences, with models that account for missing values, measurement uncertainty, and multiple testing ensuring reported changes in protein abundance are statistically robust and reproducible.^6,11,12

Proteomics in Action: Applications and Innovations

Quantitative proteomics is increasingly applied in biomedical research, from mapping protein networks and signaling pathways in systems biology to identifying proteins linked to disease onset or progression in biomarker discovery. In drug development, these approaches evaluate targets, monitor pathway modulation, and identify potential toxicities. In clinical settings, proteomic measurements are integrated with genomic and transcriptomic data to provide a comprehensive view of pathophysiology.^1,3,4

In precision medicine, quantitative proteomics supports patient stratification, biomarker validation, and treatment monitoring by capturing dynamic protein-level changes that are not evident at the genomic level.¹

These applications are increasingly supported by emerging technologies that refine proteomic analysis. Improved DIA workflows increase peptide detection consistency and deepen proteome coverage, while advances in MS sensitivity enable single-cell proteomics, enabling protein quantification at the individual-cell level. In addition, computational developments, including machine learning (ML) and enhanced statistical frameworks, improve data interpretation, reproducibility, and multi-omics integration.^5-8

As quantitative proteomics evolves, the combination of robust methodologies and technological innovation provides precise, actionable insights into protein dynamics and their expanding roles in health and disease.

References and Further Reading

1. Rojo, A. C., Heylen, D., Aerts, J., Thas, O., Hooyberghs, J., Ertaylan, G., & Valkenborg, D. (2021). Towards Building a Quantitative Proteomics Toolbox in Precision Medicine: A Mini-Review. Frontiers in Physiology, 12, 723510. DOI:10.3389/fphys.2021.723510, https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2021.723510/full
2. Macklin, A., Khan, S., & Kislinger, T. (2020). Recent advances in mass spectrometry based clinical proteomics: applications to cancer research. Clinical Proteomics, 17, 17. DOI:10.1186/s12014-020-09283-w, https://link.springer.com/article/10.1186/s12014-020-09283-w
3. Chen, G., Cheng, J., Yu, H., Huang, X., Bao, H., Qin, L., Wang, L., Song, Y., Liu, X., & Peng, A. (2021). Quantitative proteomics by iTRAQ-PRM based reveals the new characterization for gout. Proteome Science, 19, 12. DOI:10.1186/s12953-021-00180-0, https://link.springer.com/article/10.1186/s12953-021-00180-0
4. Raghuraman, B. K., Bogdanova, A., Moon, H. K., Rzagalinski, I., Geertsma, E. R., Hersemann, L., & Shevchenko, A. (2022). Median-Based Absolute Quantification of Proteins Using Fully Unlabeled Generic Internal Standard (FUGIS). Journal of Proteome Research, 21(1), 132–141. DOI:10.1021/acs.jproteome.1c00596, https://pubs.acs.org/doi/full/10.1021/acs.jproteome.1c00596
5. Wang, Z., Liu, P.-K., & Li, L. (2024). A Tutorial Review of Labeling Methods in Mass Spectrometry-Based Quantitative Proteomics. ACS Measurement Science Au, 4(4), 315–337. DOI:10.1021/acsmeasuresciau.4c00007, https://pubs.acs.org/doi/10.1021/acsmeasuresciau.4c00007
6. Zhao, L., Cong, X., Zhai, L., Hu, H., Xu, J.- Y., Zhao, W., Zhu, M., Tan, M., & Ye, B.- C. (2020). Comparative evaluation of label-free quantification strategies. Journal of Proteomics, 215, 103669. DOI:10.1016/j.jprot.2020.103669, https://www.sciencedirect.com/science/article/abs/pii/S1874391920300373
7. Krasny, L., & Huang, P. H. (2021). Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology. Molecular Omics, 17, 29–42. DOI:10.1039/D0MO00072H, https://pubs.rsc.org/en/content/articlehtml/2021/mo/d0mo00072h
8. Dubois, E., Galindo, A. N., Dayon, L., & Cominetti, O. (2022). Assessing normalization methods in mass spectrometry-based proteome profiling of clinical samples. Biosystems, 215–216, 104661. DOI:10.1016/j.biosystems.2022.104661, https://www.sciencedirect.com/science/article/pii/S0303264722000533
9. Hober, A., Rekanovic, M., Forsström, B., Hansson, S., Kotol, D., Percy, A. J., Uhlén, M., Oscarsson, J., Edfors, F., & Miliotis, T. (2023). Targeted proteomics using stable isotope labeled protein fragments enables precise and robust determination of total apolipoprotein(a) in human plasma. PLOS ONE, 18(2), e0281772. DOI:10.1371/journal.pone.0281772, https://pmc.ncbi.nlm.nih.gov/articles/PMC9931122/
10. Rozanova, S., Uszkoreit, J., Schork, K., Serschnitzki, B., Eisenacher, M., Tönges, L., Barkovits-Boeddinghaus, K., & Marcus, K. (2023). Quality Control - A Stepchild in Quantitative Proteomics: A Case Study for the Human CSF Proteome. Biomolecules, 13(3), 491. DOI:10.3390/biom13030491, https://pmc.ncbi.nlm.nih.gov/articles/PMC10046854/
11. Jin, L., Bi, Y., Hu, C., Qu, J., Shen, S., Wang, X., & Tian, Y. (2021). A comparative study of evaluating missing value imputation methods in label-free proteomics. Scientific Reports, 11, 1760. DOI:10.1038/s41598-021-81279-4, https://www.nature.com/articles/s41598-021-81279-4
12. Kong, W., Hui, H. W. H., Peng, H., & Goh, W. W. B. (2022). Dealing with missing values in proteomics data. Proteomics, 22(23–24), e2200092. DOI:10.1002/pmic.202200092, https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/pmic.202200092

Last Updated: Apr 1, 2026